Business Description
Taro Pharmaceutical Industries Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0010827181
Description
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 462.68 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 17.54 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 3.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.1 | |||||
| 3-Year EBITDA Growth Rate | -38.8 | |||||
| 3-Year EPS without NRI Growth Rate | -50.5 | |||||
| 3-Year FCF Growth Rate | -63.1 | |||||
| 3-Year Book Growth Rate | -5.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.34 | |||||
| 9-Day RSI | 56.22 | |||||
| 14-Day RSI | 53.8 | |||||
| 6-1 Month Momentum % | 25.79 | |||||
| 12-1 Month Momentum % | 71.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | |||||
| Quick Ratio | 3.03 | |||||
| Cash Ratio | 2.41 | |||||
| Days Inventory | 245.48 | |||||
| Days Sales Outstanding | 119.72 | |||||
| Days Payable | 63.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.6 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.01 | |||||
| Operating Margin % | 3.6 | |||||
| Net Margin % | 7.48 | |||||
| FCF Margin % | 14.08 | |||||
| ROE % | 2.61 | |||||
| ROA % | 2.14 | |||||
| ROIC % | 1.13 | |||||
| ROC (Joel Greenblatt) % | 18.2 | |||||
| ROCE % | 2.48 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.63 | |||||
| PE Ratio without NRI | 34.69 | |||||
| Shiller PE Ratio | 6.81 | |||||
| Price-to-Owner-Earnings | 13.31 | |||||
| PS Ratio | 2.59 | |||||
| PB Ratio | 0.89 | |||||
| Price-to-Tangible-Book | 0.9 | |||||
| Price-to-Free-Cash-Flow | 18.46 | |||||
| Price-to-Operating-Cash-Flow | 11.1 | |||||
| EV-to-EBIT | 16.91 | |||||
| EV-to-EBITDA | 9.55 | |||||
| EV-to-Revenue | 1.21 | |||||
| EV-to-Forward-Revenue | 0.82 | |||||
| EV-to-FCF | 8.6 | |||||
| Price-to-Projected-FCF | 0.72 | |||||
| Price-to-Median-PS-Value | 0.51 | |||||
| Price-to-Graham-Number | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.65 | |||||
| Price-to-Net-Cash | 3.07 | |||||
| Earnings Yield (Greenblatt) % | 5.91 | |||||
| FCF Yield % | 5.42 | |||||
| Forward Rate of Return (Yacktman) % | 0.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:TARO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taro Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 610.828 | ||
| EPS (TTM) ($) | 1.22 | ||
| Beta | 0.3 | ||
| Volatility % | 50.4 | ||
| 14-Day RSI | 53.8 | ||
| 14-Day ATR ($) | 0.282652 | ||
| 20-Day SMA ($) | 42.172 | ||
| 12-1 Month Momentum % | 71.03 | ||
| 52-Week Range ($) | 24.39 - 45.76 | ||
| Shares Outstanding (Mil) | 37.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taro Pharmaceutical Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taro Pharmaceutical Industries Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Taro Pharmaceutical Industries Ltd Frequently Asked Questions
What is Taro Pharmaceutical Industries Ltd(TARO)'s stock price today?
The current price of TARO is $42.25. The 52 week high of TARO is $45.76 and 52 week low is $24.39.
When is next earnings date of Taro Pharmaceutical Industries Ltd(TARO)?
The next earnings date of Taro Pharmaceutical Industries Ltd(TARO) is 2024-05-23 Est..
Does Taro Pharmaceutical Industries Ltd(TARO) pay dividends? If so, how much?
Taro Pharmaceutical Industries Ltd(TARO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers